Drug profile · INN
nilotinib hydrochloride
NILOTINIB HYDROCHLORIDE
nilotinib hydrochloride (NILOTINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — nilotinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
nilotinib hydrochloride (NILOTINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bcr/Abl fusion protein inhibitor
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nilotinib hydrochloride?
nilotinib hydrochloride (NILOTINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nilotinib hydrochloride?
NILOTINIB HYDROCHLORIDE is a marketed brand name for nilotinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nilotinib hydrochloride?
nilotinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.